Lawsuit against US Anesthesia Partners adds ASCs to class expansion

A recent lawsuit against U.S. Anesthesia Partners expands its scope to include patients who have received care in ambulatory surgery center (ASC) settings. The case, which initially centered around allegations of antitrust violations related to anesthesia services in hospitals, has broadened to challenge USAP’s conduct in ASCs across Texas. The class representative leading the charge claims that USAP has been overcharging for anesthesia services, as detailed in a press release by litigation firm Gibbs & Bruns released on February 12.

Moreover, the lawsuit asserts that USAP engaged in questionable practices, including acquiring rival anesthesia providers, engaging in price-fixing agreements, and participating in market-allocation schemes with certain competitors. The revised complaint now encompasses patients who have paid for anesthesia services provided by USAP throughout Texas, reflecting a broader view of the alleged violations.

In a pivotal court ruling last August, the U.S. District Court for the Southern District of Texas found merit in the plaintiffs’ claims that USAP had taken advantage of its market dominance through acquisitions, resulting in inflated prices for anesthesia services. Despite USAP’s attempts to dismiss the case in December, the judge rejected their motion, allowing the lawsuit to move forward.

Furthermore, the Federal Trade Commission (FTC) has launched a related case against USAP, suggesting a broader regulatory scrutiny of the organization’s practices. US Anesthesia Partners issued a statement through its board chairman, Scott Holliday, expressing confidence in their position and reaffirming their commitment to patient care despite the ongoing litigation. Dr. Holliday emphasized that they stand by their assertion of the original claims lacking merit, maintaining their optimism about prevailing in the legal battle.

The expansion of the lawsuit to encompass ASC settings underscores the far-reaching implications of the allegations against USAP. By including patients across various care settings in Texas, the legal action seeks to shed light on the alleged misconduct related to anesthesia services provided by US Anesthesia Partners. The scrutiny surrounding USAP’s practices highlights broader concerns about market dominance, acquisitions of rival providers, and potential antitrust violations within the anesthesia care sector.

The growing complexity of the legal battle and the involvement of regulatory agencies like the FTC signal a significant escalation in the scrutiny faced by USAP. As the case progresses, it will be essential to monitor the developments surrounding the lawsuit and the potential implications for anesthesia services in Texas and beyond. Despite USAP’s steadfast defense of their actions, the legal challenges and regulatory oversight pose a significant threat to the organization’s operations and reputation in the healthcare industry.